Vericel will report second-quarter 2026 results on July 30. The call will cover MACI, Epicel, and NexoBrid performance. Replay available through July 2027.
Vericel Corporation (NASDAQ:VCEL) scheduled its second-quarter 2026 earnings release for July 30 before the market opens. Management will host a conference call at 8:30 a.m. ET that day to discuss the results and business highlights.
The live webcast will be available on the investor relations section of Vericel's website. Presentation slides will be posted alongside the webcast. A replay will be available through July 30, 2027. Dial-in participants should use passcode 567253.
The report will cover Vericel's three marketed products: MACI for knee cartilage repair, Epicel for severe burns, and NexoBrid for burn eschar removal. MACI, an autologous cellularized scaffold, is the company's primary growth driver. Procedure volumes and burn care updates will be the key points of interest.
Vericel combines cell biology with medical technologies to serve the sports medicine and severe burn care markets. The company holds an exclusive North American license for NexoBrid from MediWound. Limited competition supports its position in these niches.
The July 30 call will be the company's first public update since its first-quarter report in April. The webcast replay will be accessible through July 30, 2027.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.